HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Advises Manufacturers To Test For Nitrosamines In All APIs, Drug Products

Executive Summary

Guidance is FDA's latest action in response to findings that over time in storage, especially at higher temperatures, levels of the probable carcinogen NDMAincreases in some ingredients, including ranitidine available in OTC heartburn remedies.

You may also be interested in...



Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want FDA to postpone its March deadline for conducting nitrosamine risk assessments. Generics executive cites “serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs

Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.

The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes

EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.

Related Content

Topics

UsernamePublicRestriction

Register

RS150434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel